Paper41501787
HVEM costimulatory domain boosts CAR T cell efficacy against solid tumors via enhanced TRAF-mediated TNF signaling.
Sun S and 14 others. Cell Commun Signal, 2026. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. HVEM costimulatory domain boosts CAR T cell efficacy against solid tumors via enhanced TRAF-mediated TNF signaling. Papers, record 41501787. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41501787
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- HVEM costimulatory domain boosts CAR T cell efficacy against solid tumors via enhanced TRAF-mediated TNF signaling.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Signal Transduction | Major topic |
| Receptors, Tumor Necrosis Factor, Member 14 | Major topic |
| Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | Major topic |
| T-Lymphocytes | Major topic |
| Tumor Necrosis Factor-alpha | Major topic |
| Neoplasms | Major topic |
| Receptors, Chimeric Antigen | Major topic |
| Animals | |
| Humans | |
| Mice | |
| Cell Line, Tumor | |
| Protein Domains |
Source PubMed
Grants9
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| KC23056 | Xuzhou Science and Technology Bureau projects | PubMed | ||
| 82303761 | National Natural Science Foundation of China | PubMed | ||
| 81972242 | National Natural Science Foundation of China | PubMed | ||
| 82473333 | National Natural Science Foundation of China | PubMed | ||
| 20KJA320006 | Natural Science Key Project of Jiangsu Provincial Education Department | PubMed | ||
| CXZX202234 | Jiangsu Provincial Key Medical Discipline, The Project of Invigorating Health Care through Science, Technology and Education | PubMed | ||
| BE2023689 | Jiangsu Province Social Development Projects | PubMed | ||
| LCZX202501 | Construction Project of High Level Hospital of Jiangsu Province | PubMed | ||
| QL-YB032 | XZHMU-QL Joint Research Fund | PubMed |
Source PubMed
References46
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37058548 | Metabolic challenges and interventions in CAR T cell therapy. | Sci Immunol | 2023 | https://conductscience.org/library/papers/37058548 | PubMed |
| 2 | 36350984 | Pooled screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies. | Sci Transl Med | 2022 | https://conductscience.org/library/papers/36350984 | PubMed |
| 3 | 9744859 | Tumor necrosis factor receptor-associated factors (TRAFs)--a family of adapter proteins that regulates life and death. | Genes Dev | 1998 | https://conductscience.org/library/papers/9744859 | PubMed |
| 4 | 36689620 | Herpes Virus Entry Mediator Costimulation Signaling Enhances CAR T-cell Efficacy Against Solid Tumors Through Metabolic Reprogramming. | Cancer Immunol Res | 2023 | https://conductscience.org/library/papers/36689620 | PubMed |
| 5 | 30272343 | Bortezomib improves adoptive carbonic anhydrase IX‑specific chimeric antigen receptor‑modified NK92 cell therapy in mouse models of human renal cell carcinoma. | Oncol Rep | 2018 | https://conductscience.org/library/papers/30272343 | PubMed |
| 6 | 34230645 | A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains. | Nat Rev Clin Oncol | 2021 | https://conductscience.org/library/papers/34230645 | PubMed |
| 7 | 38987856 | Fueling CARs: metabolic strategies to enhance CAR T-cell therapy. | Exp Hematol Oncol | 2024 | https://conductscience.org/library/papers/38987856 | PubMed |
| 8 | 33374128 | Manipulating the Metabolism to Improve the Efficacy of CAR T-Cell Immunotherapy. | Cells | 2020 | https://conductscience.org/library/papers/33374128 | PubMed |
| 9 | 26885860 | Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. | Immunity | 2016 | https://conductscience.org/library/papers/26885860 | PubMed |
| 10 | 37516527 | T cell activation and effector function in the human Jurkat T cell model. | Methods Cell Biol | 2023 | https://conductscience.org/library/papers/37516527 | PubMed |
| 11 | 40344863 | ERK1/2-MAPK signaling: Metabolic, organellar, and cytoskeletal interactions. | Curr Opin Cell Biol | 2025 | https://conductscience.org/library/papers/40344863 | PubMed |
| 12 | 38821074 | Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee. | Lancet Oncol | 2024 | https://conductscience.org/library/papers/38821074 | PubMed |
| 13 | 31758531 | The TNF-TNFR Family of Co-signal Molecules. | Adv Exp Med Biol | 2019 | https://conductscience.org/library/papers/31758531 | PubMed |
| 14 | 15120041 | Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. | Eur J Cancer | 2004 | https://conductscience.org/library/papers/15120041 | PubMed |
| 15 | 35007698 | Remodeling metabolic fitness: Strategies for improving the efficacy of chimeric antigen receptor T cell therapy. | Cancer Lett | 2022 | https://conductscience.org/library/papers/35007698 | PubMed |
| 16 | 38468828 | CAR-T Cell Therapy for T-Cell Malignancies. | Mediterr J Hematol Infect Dis | 2024 | https://conductscience.org/library/papers/38468828 | PubMed |
| 17 | 36209106 | The journey of CAR-T therapy in hematological malignancies. | Mol Cancer | 2022 | https://conductscience.org/library/papers/36209106 | PubMed |
| 18 | 38831106 | The BTLA-HVEM axis restricts CAR T cell efficacy in cancer. | Nat Immunol | 2024 | https://conductscience.org/library/papers/38831106 | PubMed |
| 19 | 39032532 | Molecular mechanism of co-stimulatory domains in promoting CAR-T cell anti-tumor efficacy. | Biochem Pharmacol | 2024 | https://conductscience.org/library/papers/39032532 | PubMed |
| 20 | 21660053 | Expanding TRAF function: TRAF3 as a tri-faced immune regulator. | Nat Rev Immunol | 2011 | https://conductscience.org/library/papers/21660053 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42924291 | Universal CAR-T cell therapy: overcoming key hurdles on the path to off-the-shelf adoption. | Med Rev (2021) | 2026 | https://conductscience.org/library/papers/42924291 | PubMed |
| 42089445 | Enhancing CAR-T Cell Efficacy in Solid Tumors by Inhibiting CCL5/VEGF-Mediated Angiogenesis. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/42089445 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41501787
GET https://conductscience.org/api/papers/v1/41501787/references?page=2